RB
Insider
Ron Bentsur
Chairman & CEORon Bentsur (Chairman & CEO) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Nuvectis Pharma, Inc. (NVCT). Across 1 priced purchase filing, the average 21-session return was -0.7% from execution and +22.3% from disclosure (delay-adjusted; derived). The largest single filing was $250K of NVCT (12,500 sh × $20.00, as filed), executed Jun 30.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-0.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+22.3%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$250K
shares × price, as filed
Last traded
Jun 30
Filed Jul 1
Median ADV $5.8M across their filed names
Open performance→Volume by month
Buys $250K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
NVCT
Nuvectis Pharma, Inc.
NVCT · 1 buy · 0 sells
1 filing
Recent filings
NVCTPURCHASE
Nuvectis Pharma, Inc.
View filing →
$250K12,500 sh × $20.00
Exec Jun 30
Filed Jul 1 · 1:39 PM ET